Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034   20/09/2024
9,500 USD (-1,86%)
(-1,86%)   20/09/2024

9 september 2024 · RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines · Persbericht

5 september 2024 · RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

3 september 2024 · New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality · Persbericht

29 augustus 2024 · RedHill Biopharma Announces First Half 2024 Business Highlights · Persbericht

26 augustus 2024 · RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma · Persbericht

21 augustus 2024 · Talicia® Launched in the United Arab Emirates · Persbericht

19 augustus 2024 · RedHill Announces Positive Obesity and Diabetes Results with Opaganib · Persbericht

16 augustus 2024 · RedHill Biopharma Announces Plan to Implement ADS Ratio Change · Persbericht

1 augustus 2024 · Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease · Persbericht

22 juli 2024 · RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien · Persbericht

9 juli 2024 · RedHill Biopharma Terminates License Agreement for Aemcolo® · Persbericht

6 mei 2024 · RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 · Persbericht

24 april 2024 · RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study · Persbericht

8 april 2024 · RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights · Persbericht

2 april 2024 · RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price · Persbericht

11 maart 2024 · RedHill Announces New USPTO Patent Covering Talicia® Through 2034 · Persbericht

5 maart 2024 · RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs · Persbericht

20 februari 2024 · RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication · Persbericht

26 januari 2024 · RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering · Persbericht

25 januari 2024 · RedHill Biopharma Announces $8 Million Registered Direct Offering · Persbericht

Mijn selecties